Cargando…
Reply to ‘Comment on ‘Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy''
| Autores principales: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5396114/ https://www.ncbi.nlm.nih.gov/pubmed/28324885 http://dx.doi.org/10.1038/bjc.2017.59 |
| _version_ | 1783230007016947712 |
|---|---|
| author | Bowyer, Samantha Prithviraj, Prashanth Lorigan, Paul Larkin, James McArthur, Grant Atkinson, Victoria Millward, Michael Khou, Muoi Diem, Stefan Ramanujam, Sangeetha Kong, Ben Liniker, Elizabeth Guminski, Alexander Parente, Phillip Andrews, Miles C Parakh, Sagun Cebon, Jonathan Long, Georgina V Carlino, Matteo S Klein, Oliver |
| author_facet | Bowyer, Samantha Prithviraj, Prashanth Lorigan, Paul Larkin, James McArthur, Grant Atkinson, Victoria Millward, Michael Khou, Muoi Diem, Stefan Ramanujam, Sangeetha Kong, Ben Liniker, Elizabeth Guminski, Alexander Parente, Phillip Andrews, Miles C Parakh, Sagun Cebon, Jonathan Long, Georgina V Carlino, Matteo S Klein, Oliver |
| author_sort | Bowyer, Samantha |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-5396114 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2017 |
| publisher | Nature Publishing Group |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-53961142018-04-11 Reply to ‘Comment on ‘Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy'' Bowyer, Samantha Prithviraj, Prashanth Lorigan, Paul Larkin, James McArthur, Grant Atkinson, Victoria Millward, Michael Khou, Muoi Diem, Stefan Ramanujam, Sangeetha Kong, Ben Liniker, Elizabeth Guminski, Alexander Parente, Phillip Andrews, Miles C Parakh, Sagun Cebon, Jonathan Long, Georgina V Carlino, Matteo S Klein, Oliver Br J Cancer Letter to the Editor Nature Publishing Group 2017-04-11 2017-03-21 /pmc/articles/PMC5396114/ /pubmed/28324885 http://dx.doi.org/10.1038/bjc.2017.59 Text en Copyright © 2017 Cancer Research UK http://creativecommons.org/licenses/by-nc-sa/4.0/ From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 4.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/ |
| spellingShingle | Letter to the Editor Bowyer, Samantha Prithviraj, Prashanth Lorigan, Paul Larkin, James McArthur, Grant Atkinson, Victoria Millward, Michael Khou, Muoi Diem, Stefan Ramanujam, Sangeetha Kong, Ben Liniker, Elizabeth Guminski, Alexander Parente, Phillip Andrews, Miles C Parakh, Sagun Cebon, Jonathan Long, Georgina V Carlino, Matteo S Klein, Oliver Reply to ‘Comment on ‘Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy'' |
| title | Reply to ‘Comment on ‘Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy'' |
| title_full | Reply to ‘Comment on ‘Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy'' |
| title_fullStr | Reply to ‘Comment on ‘Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy'' |
| title_full_unstemmed | Reply to ‘Comment on ‘Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy'' |
| title_short | Reply to ‘Comment on ‘Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy'' |
| title_sort | reply to ‘comment on ‘efficacy and toxicity of treatment with the anti-ctla-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-pd-1 therapy'' |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5396114/ https://www.ncbi.nlm.nih.gov/pubmed/28324885 http://dx.doi.org/10.1038/bjc.2017.59 |
| work_keys_str_mv | AT bowyersamantha replytocommentonefficacyandtoxicityoftreatmentwiththeantictla4antibodyipilimumabinpatientswithmetastaticmelanomaafterpriorantipd1therapy AT prithvirajprashanth replytocommentonefficacyandtoxicityoftreatmentwiththeantictla4antibodyipilimumabinpatientswithmetastaticmelanomaafterpriorantipd1therapy AT loriganpaul replytocommentonefficacyandtoxicityoftreatmentwiththeantictla4antibodyipilimumabinpatientswithmetastaticmelanomaafterpriorantipd1therapy AT larkinjames replytocommentonefficacyandtoxicityoftreatmentwiththeantictla4antibodyipilimumabinpatientswithmetastaticmelanomaafterpriorantipd1therapy AT mcarthurgrant replytocommentonefficacyandtoxicityoftreatmentwiththeantictla4antibodyipilimumabinpatientswithmetastaticmelanomaafterpriorantipd1therapy AT atkinsonvictoria replytocommentonefficacyandtoxicityoftreatmentwiththeantictla4antibodyipilimumabinpatientswithmetastaticmelanomaafterpriorantipd1therapy AT millwardmichael replytocommentonefficacyandtoxicityoftreatmentwiththeantictla4antibodyipilimumabinpatientswithmetastaticmelanomaafterpriorantipd1therapy AT khoumuoi replytocommentonefficacyandtoxicityoftreatmentwiththeantictla4antibodyipilimumabinpatientswithmetastaticmelanomaafterpriorantipd1therapy AT diemstefan replytocommentonefficacyandtoxicityoftreatmentwiththeantictla4antibodyipilimumabinpatientswithmetastaticmelanomaafterpriorantipd1therapy AT ramanujamsangeetha replytocommentonefficacyandtoxicityoftreatmentwiththeantictla4antibodyipilimumabinpatientswithmetastaticmelanomaafterpriorantipd1therapy AT kongben replytocommentonefficacyandtoxicityoftreatmentwiththeantictla4antibodyipilimumabinpatientswithmetastaticmelanomaafterpriorantipd1therapy AT linikerelizabeth replytocommentonefficacyandtoxicityoftreatmentwiththeantictla4antibodyipilimumabinpatientswithmetastaticmelanomaafterpriorantipd1therapy AT guminskialexander replytocommentonefficacyandtoxicityoftreatmentwiththeantictla4antibodyipilimumabinpatientswithmetastaticmelanomaafterpriorantipd1therapy AT parentephillip replytocommentonefficacyandtoxicityoftreatmentwiththeantictla4antibodyipilimumabinpatientswithmetastaticmelanomaafterpriorantipd1therapy AT andrewsmilesc replytocommentonefficacyandtoxicityoftreatmentwiththeantictla4antibodyipilimumabinpatientswithmetastaticmelanomaafterpriorantipd1therapy AT parakhsagun replytocommentonefficacyandtoxicityoftreatmentwiththeantictla4antibodyipilimumabinpatientswithmetastaticmelanomaafterpriorantipd1therapy AT cebonjonathan replytocommentonefficacyandtoxicityoftreatmentwiththeantictla4antibodyipilimumabinpatientswithmetastaticmelanomaafterpriorantipd1therapy AT longgeorginav replytocommentonefficacyandtoxicityoftreatmentwiththeantictla4antibodyipilimumabinpatientswithmetastaticmelanomaafterpriorantipd1therapy AT carlinomatteos replytocommentonefficacyandtoxicityoftreatmentwiththeantictla4antibodyipilimumabinpatientswithmetastaticmelanomaafterpriorantipd1therapy AT kleinoliver replytocommentonefficacyandtoxicityoftreatmentwiththeantictla4antibodyipilimumabinpatientswithmetastaticmelanomaafterpriorantipd1therapy |